Opportunity to join Graybug Vision, a clinical stage biopharmaceutical company focused on developing transformative medicines to treat diseases of the retina and optic nerve. Graybug’s lead product candidate, GB-102, a microparticle depot formulation of the pan-VEGF inhibitor targeting a six-month or longer dosing regimen, is in phase 2 clinical development for wet age-related macular degeneration. Two additional compounds are in pre-clinical development.
As the Senior Director, Quality Assurance, reporting to the Chief Operations Officer, you are an innovative leader with a mission to improve the standard of care in ophthalmology by working with external and internal experts on innovative approaches to improve disease management, reduce healthcare burdens and ultimately deliver better clinical outcomes.